IPP Bureau
FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes
By IPP Bureau - October 29, 2025
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
AskBio’s gene therapy shows promising 12-month results for heart failure
By IPP Bureau - October 29, 2025
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines
By IPP Bureau - October 29, 2025
FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma
By IPP Bureau - October 29, 2025
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain
By IPP Bureau - October 29, 2025
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women
By IPP Bureau - October 29, 2025
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Orion secures license to Abzena’s next-generation cancer antibody
By IPP Bureau - October 29, 2025
The antibody was designed and developed at Abzena’s Cambridge, UK,
Novartis completes acquisition of Tourmaline Bio
By IPP Bureau - October 29, 2025
Tourmaline is now an indirect wholly owned subsidiary of Novartis
FDA approves Alembic's Ticagrelor Tablets, 60 mg
By IPP Bureau - October 29, 2025
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Sai Life Sciences to double process R&D capacity with new facility in Hyderabad
By IPP Bureau - October 28, 2025
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Sanofi India appoints Deepak Arora as MD
By IPP Bureau - October 28, 2025
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies
By IPP Bureau - October 28, 2025
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Akums breaks ground for its first overseas manufacturing facility in Zambia
By IPP Bureau - October 28, 2025
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Sigachi Industries posts Q2 FY2026 consolidated profit at Rs. 10.68 Cr
By IPP Bureau - October 27, 2025
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
Zydus receives approval from Health Canada for Mesalamine suppositories
By IPP Bureau - October 27, 2025
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
